The Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr (SAPPHIRE): A National Study
What Is SAPPHIRE?
Inflammatory bowel disease (IBD) is a condition in which the body’s immune system reacts inappropriately and causes ongoing inflammation in the digestive tract. To manage this, many patients are often treated with immunosuppressants. Beca...
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder c...
Age: 18 years - 66+
Gender: All
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
The purpose of this first-in-human study is to identify a recommend dose(s) for
subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing
doses of M0324, primarily looking at safety, but also preliminary signs of efficacy,
pharmacokinet...
Age: 18 years - 66+
Gender: All
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
The NODULE-SHOCK trial is a prospective, investigator-initiated, single-center,
randomized controlled trial designed to compare the efficacy of intravascular lithotripsy
(IVL) with or without rotational atherectomy (RA) in patients with coronary calcified
nodules (Co...
Age: 18 years - 66+
Gender: All
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
The purpose of this research study is to evaluate what type of treatment will be beneficial for people with Crohn's disease and difficult to treat inflammation in the small bowel. Current therapies are used to control the inflammation due to Crohn's disease in your dige...
Age: 18 - 80 years
Gender: All
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
The purpose of this research study is to evaluate what type of treatment will be
beneficial for people with Crohn's disease and difficult to treat inflammation in the
small bowel. Current therapies are used to control the inflammation due to Crohn's
disease in your d...
Age: 18 - 80 years
Gender: All
MAGIC Ruxolitinib for aGVHD
This clinical trial will study ruxolitinib-based treatment of acute
graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell
transplant. Acute GVHD occurs when donor cells attack the healthy tissue of the body. The
most common symptoms ...
Age: 18 years - 66+
Gender: All
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
This real-world, international registry aims to evaluate the current experience with
sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease
(ACHD) patients by investigating the prescription patterns, safety, tolerability, and
potential b...
Age: 18 years - 66+
Gender: All
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
This real-world, international registry aims to evaluate the current experience with
sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease
(ACHD) patients by investigating the prescription patterns, safety, tolerability, and
potential b...
Age: 18 years - 66+
Gender: All
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety,
tolerability, cellular kinetics, and biomarker changes in C-peptide over time of
GNTI-122, an investigational cell therapy manufactured from a participant's own blood
cells in adult par...
Age: 18 - 45 years
Gender: All
Human Milk Research Study
What is the purpose of the study?
The maternal RSV vaccine was licensed in 2023 for prevention of RSV-associated lower respiratory tract disease in infants up to six months of age. Maternal immunization protects infants via antibodies transferred in utero. Additional be...
Age: 18 - 50 years
Gender: Female
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
This will be a pilot multi-arm clinical trial investigating the feasibility of 6 weeks of Lumbrokinase (LK) as an intervention in three clinical cohorts:
Long Covid (LC)
Post-treatment Lyme disease syndrome (PTLDS)
Myalgic encephalomyelitis/chronic fatigue syndrome (ME...
Age: 18 years - 66+
Gender: All
Multi-omics Study in Citrin Deficiency
Citrin deficiency (CD) is an underdiagnosed and understudied condition characterized by
several distinct phenotypes: 1) neonatal intrahepatic cholestasis caused by citrin
deficiency (NICCD), 2) the adaptation or silent period, 3) "failure to thrive and
dyslipidemia" ...
Age: 0 - 100 years
Gender: All
Multi-omics Study in Citrin Deficiency
Citrin deficiency (CD) is an underdiagnosed and understudied condition characterized by
several distinct phenotypes: 1) neonatal intrahepatic cholestasis caused by citrin
deficiency (NICCD), 2) the adaptation or silent period, 3) "failure to thrive and
dyslipidemia" ...
Age: 0 - 100 years
Gender: All
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Induction therapy approaches in recent years have evolved, now utilizing triple or
quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies,
proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and steroids, patients
achieve long...
Age: 70 years - 66+
Gender: All
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Induction therapy approaches in recent years have evolved, now utilizing triple or
quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies,
proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and steroids, patients
achieve long...
Age: 70 years - 66+
Gender: All
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will
evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart
(also known as RO7790121) in participants with moderately to severely active Crohn's
disease (...
Age: 16 - 80 years
Gender: All
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
The purpose of this research is to develop and validate a single gene Non-Invasive
Prenatal Test. The development of this investigational single-gene noninvasive prenatal
testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy
(SMA), Sic...
Age: 18 years - 66+
Gender: All
EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND)
The purpose of this research is to develop and validate a single gene Non-Invasive
Prenatal Test. The development of this investigational single-gene noninvasive prenatal
testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy
(SMA), Sic...
Age: 18 years - 66+
Gender: All
Enfortumab Vedotin Plus Pembrolizumab with Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus
pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and
cystoscopy with TURBT of any visible tumor and/or resection site plus random biopsies
using a r...
Age: 18 years - 66+
Gender: All